{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Show Me The Evidence","title":"From the FDA to the operating theatre: how proficiency rewrote the rules of surgical training","html":"","width":"100%","height":180,"duration":2782,"description":"Guest: Professor Anthony G Gallagher Host: Patrick Kiely Episode focus: two landmark studies, the 2004 JAMA carotid stenting paper and the Copernicus arthroscopy trialEpisode summaryProfessor Tony Gallagher, the founder of Proficiency-Based Progression (PBP), joins Patrick Kiely to revisit two studies that changed how we think about surgical competence.The first is the 2004 JAMA paper describing a closed-door meeting at which the US Food and Drug Administration agreed, for the first time, that simulation training should form part of how doctors are approved to perform a procedure. The second is the Copernicus trial in shoulder arthroscopy, which showed that a simulator only improves training when it is paired with validated metrics and a clear proficiency benchmark.Together they make a simple, evidence-led case: competence should be measured by the skill a clinician can demonstrate, not by years served or cases counted.Chapters0:00 Introduction 0:50 Inside the 2004 closed-door FDA meeting on carotid stenting 4:43 Why carotid stenting forced the conversation 7:25 Skill over specialty: ending the turf war 9:44 The FDA precedent: simulation becomes part of credentialing 12:03 Why procedure volume is a crude proxy for competence 14:17 Why the argument had to appear in JAMA 16:22 A homogeneous skill set, devices, and patient safety 20:42 The Copernicus Initiative: a paradigm shift in training 22:53 Three groups, one lesson: a simulator alone is not enough 25:44 The results: 56 per cent fewer errors and the 7.5 times finding 27:53 The trainees who did not pass, and distributed training 30:37 Pass the cognitive exam before the skills lab 32:33 Task deconstruction: 45 steps and 77 possible errors 36:04 Errors versus sentinel errors: why minor errors matter most 39:09 Why fidelity is not the point 41:59 Why a multi-site trial mattered 44:20 Where to start: begin with the metricsKey pointsCarotid artery stenting is high risk and crossed three specialties, so the FDA needed...","thumbnail_url":"https://img.transistorcdn.com/JPxx16guuIWtjNqUkS-VeCJVeP1R-gkQQ7xD4SsyqqM/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lZGMy/MjkyM2UxYTkzZmM5/ZjVkMmI4MzAzOTM0/YTIzYi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}